Industry Briefs: October 22, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Industry Briefs: October 22, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Oct 25, 2012

Company News

AMRI has extended its API supply agreement with Shire. Read More

Aptuit has announced the offering of antibacterial studies from a single site, the Aptuit Center for Drug Discovery & Development in Verona, Italy.

The National Institute of Allergy and Infectious Diseases has awarded Pfenex a contract to develop an alternative delivery method for its recombinant protective antigen (rPA)-based anthrax vaccine. Read More

Pluristem Therapeutics has achieved a milestone towards the completion of its new GMP manufacturing facility for commercial production of the company’s Placental eXpanded cells. Read More

The United States Pharmacopeial Convention (USP) has selected the Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved spectral libraries to pharmaceutical manufacturers. Read More

People News

AMRI has appointed Steven R. Hagen as senior vice-president of pharmaceutical development and manufacturing. Read More

Cobra Biologics has appointed John Birch, former chief scientific officer for Lonza Biopharmaceuticals, as a nonexecutive director. Read More

ISPE has announced its 2012–2013 board of directors election results, including Charlotte Enghave Fruergaard as chair and Damian Greene as vice-chair. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Featured Jobs

More Jobs
10/25/2012
 Click here